LOPROX
LOE ApproachingNDATOPICALSHAMPOO
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPROX is a topical antifungal shampoo approved by the FDA in 2003 for treatment of fungal scalp infections. The active ingredient is ciclopirox, which disrupts fungal cell membrane integrity. It is indicated for seborrheic dermatitis and other scalp fungal conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling potential team restructuring and shift toward defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOPROX offers limited growth trajectory given LOE status and zero linked job opportunities, making it a consolidation or legacy brand assignment. Career progression depends on defending market share and managing generic transition rather than driving innovation or expansion.
Brand ManagerField Sales Representative
Worked on LOPROX at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.